AI-extracted from the 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 revenue rose 14.9% to $390.0 million and gross margin expanded to 67.9%, but SG&A up 24.1% — including $6.9M of Boston Scientific merger costs — left income from operations flat at $41.0 million.
Biggest Revenue Drivers
Thrombectomy$259.0M+12.5% YoY
Higher sales volume in the United States from further market penetration of existing products; prices substantially unchanged
Embolization and Access$131.1M+20.0% YoY
Higher U.S. sales volume from further market penetration of new and existing products; prices substantially unchanged
Biggest Revenue Drivers
Total revenue: $390.0M+14.9% YoY
Thrombectomy$259.0M+12.5% YoY
Higher sales volume in the United States from further market penetration of existing products; prices substantially unchanged
Within Thrombectomy
United States$305.4M+17.1% YoY
International$84.6M+7.6% YoY
Embolization and Access$131.1M+20.0% YoY
Higher U.S. sales volume from further market penetration of new and existing products; prices substantially unchanged
Largest Expense Items
Sales, general and administrative$198.5M+24.1% YoY
$1.8M more product development and testing, $1.3M personnel, offset by $0.9M lower other R&D on timing
Provision for income taxes$11.4M24.6% effective rate vs 0.1%
Decrease in excess tax benefits from stock-based compensation in the U.S. jurisdiction
Margins: Gross margin rose 1.9 points to 67.9% from 66.0%, primarily driven by favorable product mix across regions. Operating margin fell to 10.5% from 12.0% as SG&A reached 50.9% of revenue.
Watch Items from the Filing
Pending Boston Scientific merger at $374 per share, ~$14.5B enterprise value, expected to close in 2026 subject to regulatory approvals.
Company termination fee of $525.0 million payable to Boston Scientific under specified circumstances; Parent owes $900.0 million in certain cases.
Effective tax rate jumped to 24.6% from 0.1% a year ago, cutting net income to $34.8M from $45.3M despite higher operating income.
International revenue grew only 7.6% versus 17.1% in the U.S., falling to 21.7% of total from 23.2%; no FX hedging in place.
Costa Rica manufacturing project cost estimate increased about $28 million during the six months on design scope refinements; $50.6M paid to date of ~$88M.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
About Penumbra Inc (PEN): stock profile, AI score and financials
Penumbra Inc (PEN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PEN at 67.4/100 on a composite quality score built from its SEC filings, placing it at rank #369 of 2,925 stocks — the top 25% of the AI-ranked universe. PEN scores in the top quartile across balance sheet strength (82.8), earnings quality (79.5). Shareholder dilution risk is elevated at 26.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Penumbra Inc reports quarterly revenue of $390.0M, net income of $34.8M, an operating margin of 10.5%. Top institutional holders of PEN by reported 13-F value include BlackRock, HBK INVESTMENTS L P, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. PEN trades on the NYSE exchange and files with the SEC under CIK 1321732. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PEN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Penumbra Inc directly from SEC EDGAR.